Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent
in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy …

Advances in nanomedicine, including early cancer detection, targeted drug delivery, and
personalized approaches to cancer treatment are on the rise. For example, targeted drug …

Phagocytes are key cellular participants determining important aspects of host exposure to
nanomaterials, initiating clearance, biodistribution and the tenuous balance between host …

Cancer nanotherapeutics are progressing at a steady rate; research and development in the
field has experienced an exponential growth since early 2000's. The path to the …

Enhanced permeability of the tumor vasculature allows macromolecules to enter the tumor
interstitial space, whereas the suppressed lymphatic filtration allows them to stay there. This …

Nanoparticle drug delivery to the tumor is impacted by multiple factors: nanoparticles must
evade clearance by renal filtration and the reticuloendothelial system, extravasate through …

Therapeutic nanoparticles (TNPs) aim to deliver drugs more safely and effectively to
cancers, yet clinical results have been unpredictable owing to limited in vivo understanding …

For decades, nanomedicines have been reported as a potential means to overcome the
limitations of conventional drug delivery systems by reducing side effects, toxicity and the …

Extended circulation of nanoparticles in blood is essential for most clinical applications.
Nanoparticles are rapidly cleared by cells of the mononuclear phagocyte system (MPS) …

While plasma proteins can influence the physicochemical properties of nanoparticles, the
adsorption of protein to the surface of nanomaterials can also alter the structure and function …